Reason for request
Extension of indication
Clinical Benefit
Clinical Added Value
| moderate |
LUCENTIS 10 mg/mL, solution for injection provides a moderate improvement in actual benefit (level III) in terms of efficacy in comparison with VISUDYNE in the treatment of visual impairment due to choroidal neovascularisation secondary to pathologic myopia. |
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
1qDW2nbWYn3xAmk7
